Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03368807 · ClinicalTrials.gov registry record

Assessment of Mealtime Bolus Insulin Behavior

A clinical trial of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.

Completed
Registry status
79
Enrollment target
6
Study locations

NCT03368807: Completed study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.

NCT03368807 is a study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Eli Lilly and Company. The registered enrollment target is 79 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03368807, a study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
79 participants
Enrollment target
6
Study locations

Study Summary

The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.

Primary Outcome

The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using blinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively.

Interventions

  • DEVICE Continuous Glucose Monitoring
  • DRUG Insulin Lispro

Study Locations (6)

California

  • AMCR Institute, Inc. - Escondido
  • Science 37 Inc - Los Angeles
  • Coastal Metabolic Research Ctr - Ventura

Idaho

  • Rocky Mountain Diabetes and Osteoporosis Center - Idaho Falls

Iowa

  • Iowa Diabetes & Endocrinology Research Center - West Des Moines

Utah

  • Advanced Research Institute - Ogden

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2017-12-11
Est. Completion 2018-07-23
Eli Lilly and Company

1,341 total trials

What the finished NCT03368807 record still lists

NCT03368807 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Continuous Glucose Monitoring is the first listed.

NCT03368807 lists 6 locations in 4 states (California, Idaho, Iowa).

Frequently Asked Questions

What is clinical trial NCT03368807 about?

NCT03368807 is a clinical study titled "Assessment of Mealtime Bolus Insulin Behavior". The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM)...

What is the current status of trial NCT03368807?

This trial is currently completed. The enrollment target is 79 participants. The study started on 2017-12-11. Estimated completion is 2018-07-23.

What conditions does trial NCT03368807 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT03368807?

The interventions under investigation include: Continuous Glucose Monitoring (DEVICE), Insulin Lispro (DRUG).

Who is sponsoring clinical trial NCT03368807?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03368807 being conducted?

This trial has 6 study locations across California, Idaho, Iowa, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03368807's enrollment target sits among peer trials

79 221st of 348 higher than 128 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05798897 · 79 participants · Phase 1

    Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

  • NCT06042439 · 79 participants · NA

    AM vs PM Exercise Training

  • NCT06223555 · 79 participants · NA

    Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03368807, the US trial registry maintained by the National Library of Medicine. NCT03368807 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.